STK38 and fatty liver disease: Reduced STK38 (HFD+shRNA STK38) ameliorates HFD-induced impaired glucose tolerance, insulin resistance, and hepatic steatosis in HFD mice mainly by controlling hypophosphorylation of TBK1.